Mon panier

CD46

CD46 Informations sur la molécule

Nom anglaisMembrane cofactor proteinNombre de médicaments commercialisés0
Nombre de médicaments cliniques5Alias de la cibleTLX,MCP,CD46,CD46 Molecule,Membrane Cofactor Protein (CD46, Trophoblast-Lymphocyte Cross-Reactive Antigen),Antigen Identified By Monoclonal Antibody TRA-2-10,CD46 Molecule, Complement Regulatory Protein,CD46 Antigen, Complement Regulatory Protein,Trophoblast Leukocyte Common Antigen,MIC10,Trophoblast-Lymphocyte Cross-Reactive Antigen,Complement Membrane Cofactor Protein,Trophoblast Leucocyte Common Antigen,Measles Virus Receptor,CD46 Antigen,TRA2.10,AHUS2,Membrane cofactor protein,MGC26544
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisMembrane cofactor protein
Alias de la cibleTLX,MCP,CD46,CD46 Molecule,Membrane Cofactor Protein (CD46, Trophoblast-Lymphocyte Cross-Reactive Antigen),Antigen Identified By Monoclonal Antibody TRA-2-10,CD46 Molecule, Complement Regulatory Protein,CD46 Antigen, Complement Regulatory Protein,Trophoblast Leukocyte Common Antigen,MIC10,Trophoblast-Lymphocyte Cross-Reactive Antigen,Complement Membrane Cofactor Protein,Trophoblast Leucocyte Common Antigen,Measles Virus Receptor,CD46 Antigen,TRA2.10,AHUS2,Membrane cofactor protein,MGC26544
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques5
Phase de R&D la plus avancéePhase 2 Clinical

CD46 Liste de produits

  • Attribut

    Protein (5)

  • Bibliothèque de produits

    En ligne (5)

  • Espèces

    Human (5)

  • Étiquette

    His Tag (4)Fc Tag (1)

  • Marqueur

    Unconjugated (2)FITC Labeled (1)APC Labeled (1)PE Labeled (1)

CD46Contexte de la molécule

Complement regulatory protein CD46 is also known as membrane Cofactor Protein (MCP), is a type I membrane protein and is a regulatory part of the complement system. CD46 is expressed by all cells except erythrocytes. MCP acts as a cofactor for complement factor I, a serine protease which protects autologous cells against complement-mediated injury by cleaving C3b and C4b deposited on host tissue, and also acts as a costimulatory factor for T-cells which induces the differentiation of CD4+ into T-regulatory 1 cells. In T-cells by binding to CD46, A number of viral and bacterial pathogens seem to exploit this property and directly induce an immunosuppressive phenotype. Defects in CD46 are a cause of susceptibility to hemolytic uremic syndrome atypical type 2 (AHUS2).

CD46Alias de la molécule

CD46,AHUS2,MCP,MIC10,TLX,TRA2.10

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
Anti-CD46 antibody drug conjugate (Fortis Therapeutics)FG-3246; FOR-46Phase 2 ClinicalUniversity Of California San DiegoMultiple Myeloma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
EnadenotucirevColoAd-1; Oncolytic Ad11/Ad3Phase 1 ClinicalAkamis Bio LtdCarcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Colorectal Neoplasms; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms
Details
AugmAbBRM-132Phase 1 ClinicalCompliment CorpLymphoma, Non-Hodgkin; Neoplasms
Details
YS-5YS-5Phase 1 ClinicalFortis Therapeutics Inc, United States Department Of DefenseProstatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
FG-318089Zr-DFO-YS-5; 89Zr-DFO-YS5Phase 1 ClinicalFortis Therapeutics IncMultiple Myeloma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments cliniques